Scott Whitcup joins Questcor board
This article was originally published in Scrip
Biopharmaceutical company Questcor has appointed Dr Scott Whitcup to its board of directors. Dr Whitcup is currently executive vice-president of research and development and chief scientific officer at Allergan. He joined Allergan in 2000 and has served as executive VP since 2004 and CSO since 2009. Prior to this, he served as clinical director of the National Eye Institute at the National Institutes of Health.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.